Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124791162 | 12479116 | 2 | F | 201312 | 20160722 | 20160620 | 20160801 | EXP | TW-TEVA-669784ACC | TEVA | 66.00 | YR | F | Y | 0.00000 | 20160801 | MD | TW | TW |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124791162 | 12479116 | 1 | PS | BENDAMUSTINE HYDROCHLORIDE. | BENDAMUSTINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 22249 | POWDER FOR INJECTION | ||||||||||
| 124791162 | 12479116 | 2 | SS | VELCADE | BORTEZOMIB | 1 | Intravenous (not otherwise specified) | 0 | POWDER FOR INJECTION | ||||||||||
| 124791162 | 12479116 | 3 | SS | DOXORUBICIN | DOXORUBICIN | 1 | Unknown | 0 | SOLUTION FOR INJECTION | ||||||||||
| 124791162 | 12479116 | 4 | SS | ARA-C | CYTARABINE | 1 | Unknown | 0 | |||||||||||
| 124791162 | 12479116 | 5 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | 0 | |||||||||||
| 124791162 | 12479116 | 6 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | 0 | |||||||||||
| 124791162 | 12479116 | 7 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | 0 | |||||||||||
| 124791162 | 12479116 | 8 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | 0 | |||||||||||
| 124791162 | 12479116 | 9 | SS | PREDNISONE. | PREDNISONE | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124791162 | 12479116 | 1 | Mantle cell lymphoma |
| 124791162 | 12479116 | 2 | Mantle cell lymphoma |
| 124791162 | 12479116 | 3 | Mantle cell lymphoma |
| 124791162 | 12479116 | 4 | Mantle cell lymphoma |
| 124791162 | 12479116 | 5 | Mantle cell lymphoma |
| 124791162 | 12479116 | 7 | Mantle cell lymphoma |
| 124791162 | 12479116 | 8 | Mantle cell lymphoma |
| 124791162 | 12479116 | 9 | Mantle cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124791162 | 12479116 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124791162 | 12479116 | Off label use | |
| 124791162 | 12479116 | Therapeutic response decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124791162 | 12479116 | 1 | 201312 | 0 | ||
| 124791162 | 12479116 | 2 | 201301 | 201309 | 0 | |
| 124791162 | 12479116 | 3 | 201209 | 0 | ||
| 124791162 | 12479116 | 4 | 201301 | 0 | ||
| 124791162 | 12479116 | 5 | 201209 | 0 | ||
| 124791162 | 12479116 | 6 | 201209 | 0 | ||
| 124791162 | 12479116 | 7 | 201209 | 0 | ||
| 124791162 | 12479116 | 8 | 201209 | 0 | ||
| 124791162 | 12479116 | 9 | 201209 | 0 |